GBA Presents: THE GREEN MARKET

Keep your eyeballs on OCGN, it's going to move. Which direction? Has huge short selling, so good news brings the squeeze. Bad news equals death. Gamble anyone? Sky high IV in the options market.
  • The World Health Organization (WHO) has further delayed the emergency use authorization (EUA) for Covaxin, a COVID-19 vaccine developed in India. Ocugen Inc (NASDAQ: OCGN) is the U.S. partner for the vaccine.

  • According to sources, the global body has sent more technical queries to its manufacturer Bharat Biotech.

  • Without EUA, Covaxin would not be considered an accepted vaccine by most countries around the world. WHO's queries for Bharat Biotech come despite the drugmaker asserting that it has submitted all data required for clearance.

  • The indication of a delay comes merely days after the Union Health Ministry hinted that the global body was likely to give its nod anytime soon.
 
-->
Palantir likely to announce $90M contract this week, says William Blair 07:24 PLTR William Blair analyst Kamil Mielczarek says his firm's government tracker shows that in addition to Peraton winning a $2.7B five-year data center Department of Homeland Security single-company contract and Booz Allen's (BAH) Liberty IT winning a $735M five-year Department of Veterans Affairs ask order, Palantir recently won a $90M four-year contract to provide its Foundry software. Palantir will likely announce the contract early next week, Mielczarek tells investors in a research note. While this new contract is a positive for Palantir, it was Palantir's "only significant new government contract in the September quarter that we are aware of," adds the analyst. Mielczarek does not believe Palantir's recent bookings are sufficient to prevent its government revenue growth rate from rapidly decelerating over the next year. As such, he keeps an Underperform rating on the shares.
 
CaptainObvious said:
Keep your eyeballs on OCGN, it's going to move. Which direction? Has huge short selling, so good news brings the squeeze. Bad news equals death. Gamble anyone? Sky high IV in the options market.
  • The World Health Organization (WHO) has further delayed the emergency use authorization (EUA) for Covaxin, a COVID-19 vaccine developed in India. Ocugen Inc (NASDAQ: OCGN) is the U.S. partner for the vaccine.

  • According to sources, the global body has sent more technical queries to its manufacturer Bharat Biotech.

  • Without EUA, Covaxin would not be considered an accepted vaccine by most countries around the world. WHO's queries for Bharat Biotech come despite the drugmaker asserting that it has submitted all data required for clearance.

  • The indication of a delay comes merely days after the Union Health Ministry hinted that the global body was likely to give its nod anytime soon.
More...
I forgot about these guys. I highlighted them back in April when the stock triggered a volume alert for me.
https://www.elitetrader.com/et/threads/gbas-2021-stock-phantasma.354298/page-414#post-5371509

Good find. Definitely one to keep an eye on this week. I would think momentum alone from those just betting on the come will send it above $8.
The borrow rate isn't that bad, considering it has (as of 9/24) 26% of the float short. There's a big gap between its current price and its price last year. Lot of air in between lol.
Usually the request for more data is a good sign. Usually.
Stoney needs to dig into it, he's good at these things.

About COVAXIN


COVAXIN, India's COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied.


In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to available data for several other vaccines, COVAXIN is packaged in multi-dose vials that can be stored at 2-8⁰C.


About Ocugen, Inc.


Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com
 
You must log in or register to reply here.
Back
Top